Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population

BMJ Open

Volumn 5, Issue 9, 2015, Pages

  Zhang, Yongyuan ^a,b   Zhang, Tao ^a   Zhang, Chengqi ^c   Tang, Fang ^c   Zhong, Nvjuan ^a   Li, Hongkai ^a   Song, Xinhong ^c   Lin, Haiyan ^c   Liu, Yanxun ^a   Xue, Fuzhong ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATTRIBUTABLE RISK; BAYESIAN NETWORK; CHINESE; COHORT ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HAN CHINESE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; URBAN POPULATION; BAYES THEOREM; BODY MASS; CHINA; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE COURSE; ECHOGRAPHY; FORECASTING; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

GLUCOSE BLOOD LEVEL;

ADULT; BAYES THEOREM; BLOOD GLUCOSE; BODY MASS INDEX; CHINA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; ULTRASONOGRAPHY;

EID: 84949457218     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008204     Document Type: Article

References (68)

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-62.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
3. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
5. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-9.
6. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-14.
7. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
8. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005;28:1518-23.
9. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005;90:1578-82.
10. Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999;18:353-8.
11. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
12. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-17.
13. Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care 2003;26:3351-2.
14. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020-3.
15. Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009;104:861-7.
16. Fan JG, Li F, Cai XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007;22:1086-91.
17. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
18. Pacifico L, Anania C, Martino F, et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010;52:1643-51.
19. Chavez-Tapia NC, Mendez-Sanchez N, Uribe M. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2006;144:379; author reply 80.
20. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8.
21. Souza MR, Diniz Mde F, Medeiros-Filho JE, et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012;49:89-96.
22. Zhang T, Zhang Y, Zhang C, et al. Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. PLoS ONE 2014;9: e96651.
23. Smits MM, Ioannou GN, Boyko EJ, et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroen Hepatol 2013;28:664-70.
24. Rector RS, Thyfault JP, Wei YZ, et al. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroentero 2008;14:185-92.
25. Fan JG, Zhu JN, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroen Hepatol 2005;20:1825-32.
26. Ryoo JH, Choi JM, Moon SY, et al. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis 2013;227:398-403.
27. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708-15.
28. Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015;47:181-90.
29. Mohan V, Farooq S, Deepa M, et al. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pr 2009;84:84-91.
30. Zhang T, Zhang C, Zhang Y, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis 2015;240:144-8.
31. Tsai CH, Li TC, Lin CC. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J 2008;101:900-5.
32. Hamaguchi M, Takeda N, Kojima T, et al. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroentero 2012;18:1508-16.
33. Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastr Nutr 2009;49:442-9.
34. Castro-Martinez MG, Banderas-Lares DZ, Ramirez-Martinez JC, et al. Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir 2012;80:128-33.
35. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901-10.
36. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013;43:51-64.
37. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
38. Pearl J. Causality: models, reasoning and inference. Cambridge University Press, 2009.
39. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37-48.
40. Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. [Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases]. Zhonghua Gan Zang Bing Za Zhi 2006;14:161-3.
41. Lu YH, Lu JM, Wang SY, et al. [Comparison of the diagnostic criteria of metabolic syndrome by International Diabetes Federation and that by Chinese Medical Association Diabetes Branch]. Zhonghua Yi Xue Za Zhi 2006;86:386-9.
42. Schafer JL. Analysis of incomplete multivariate data. Taylor & Francis, 1997.
43. Jensen FV. Bayesian networks and decision graphs. Springer, 2001.
44. Kjaerulff UB, Madsen AL. Bayesian networks and influence diagrams: a guide to construction and analysis. Springer, 2007.
45. Lauritzen SL, Datalogi AUIfESAfMo. The EM algorithm for graphical association models with missing data. University of Aalborg, Institute for Electronic Systems, Department of Mathematics and Computer Science, 1991.
46. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992;3:143-55.
47. Pearl J. Direct and indirect effects. Proceedings of the Seventeeth Conference on Uncertainty in Artificial Intelligence; San Francisco: Morgan Kaufmann, 2001:411-20.
48. van der Laan MJ, Petersen ML. Estimation of direct and indirect causal effects in longitudinal studies. UC Berkley, Division of Biostaistics Working Paper Series 155. 2004.
49. Petersen ML, Sinisi SE, van der Laan MJ. Estimation of direct causal effects. Epidemiology 2006;17:276-84.
50. Andersen SK, Olesen KG, Jensen FV, et al. Hugin-a Shell for Building Bayesian Belief Universes for Expert Systems. Proceedings of the Eleventh International Joint Conference on Artificial Intelligence; 1989:1080-5.
51. Anders L, Madsen ML, Uffe B, et al. The Hugin Tool for Learning Bayesian Networks. Proceedings of 7th European Conference on Symbolic and Quantitative Approaches to Reasoning with Uncertainty. 2003;Vol. 2711:594-605.
52. Burgert TS, Taksali SE, Dziura J, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006;91:4287-94.
53. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89.
54. Goodpaster BH, Krishnaswami S, Harris TB, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005;165:777-83.
55. Andre P, Balkau B, Vol S, et al. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007;30:2355-61.
56. Giral P, Jacob N, Dourmap C, et al. Elevated gamma-glutamyltransferase activity and perturbed thiol profile are associated with features of metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:587-93.
57. Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012;55:1406-15.
58. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27:127-33.
59. Oda E, Kawai R, Watanabe K, et al. Prevalence of metabolic syndrome increases with the increase in blood levels of gamma glutamyltransferase and alanine aminotransferase in Japanese men and women. Intern Med 2009;48:1343-50.
60. Onat A, Can G, Ornek E, et al. Serum γ-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring) 2012;20:842-8.
61. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012;32:22-9.
62. Li G, Hu H, Shi W, et al. Elevated hematocrit in nonalcoholic fatty liver disease: a potential cause for the increased risk of cardiovascular disease? Clin Hemorheol Microcirc 2012;51:59-68.
63. Liu W, Baker SS, Baker RD, et al. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS ONE 2011;6:e24363.
64. Yilmaz Y. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Clin Chim Acta 2012;413:1190-3.
65. Yu C, Xu C, Xu L, et al. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012;56:241-7.
66. Carulli L, Ballestri S, Lonardo A, et al. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med 2013;8:297-305.
67. Ballestri S, Romagnoli D, Nascimbeni F, et al. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 2015;9: 603-27.
68. Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012;32:1242-52.